Pluristem Therapeutics reported a Q4 2021 quarter with no revenue, consistent with its development-stage biotech profile. Revenue was 0, gross profit 0, and net income declined to a loss of $14.57 million for the quarter, driven by research and development expenses of $8.49 million and general & administrative expenses of $6.10 million. EBITDA stood at approximately $(14.23) million, and the operating loss was $(14.59) million, reflecting ongoing investments in PLX-based programs and platform licenses. Despite negative earnings, the company exhibited a favorable liquidity position, ending the period with roughly $31.84 million in cash and about $64.95 million in total cash and short-term investments, supported by financing activities that added approximately $24.41 million and yielded a net cash increase of $18.99 million for the quarter.
While the near-term top-line remains non-existent, PSTI’s strategic leverage lies in its PLX-derived cell therapies (notably PLX-PAD) across multiple clinical programs, including Phase III for recovery after hip fracture, Phase II for ARDS associated with COVID-19, and Phase I/II for graft-versus-host disease, along with PLX-R18 programs and international collaborations (South Korea license, NASA collaboration). The quarter underscores the cash burn typical of late-stage development-stage biotechs and places ongoing emphasis on financing flexibility and clinical readouts as key near-term catalysts. Investors should monitor trial progress, data readouts, potential licensing deals, and any changes in burn rate as assets move through late-stage development.